

Pavan Kumar Prathipati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3574987/publications.pdf>

Version: 2024-02-01

18
papers

392
citations

840119

11
h-index

940134

16
g-index

21
all docs

21
docs citations

21
times ranked

612
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening. <i>Antiviral Research</i> , 2018, 151, 78-86.	1.9	53
2	Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. <i>Aids</i> , 2017, 31, 469-476.	1.0	45
3	Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics. <i>Current HIV Research</i> , 2018, 15, 411-421.	0.2	40
4	Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. <i>Journal of Controlled Release</i> , 2019, 294, 216-225.	4.8	37
5	Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study. <i>Antiviral Research</i> , 2018, 156, 85-91.	1.9	36
6	A potential long-acting bicittegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study. <i>Antiviral Research</i> , 2019, 167, 83-88.	1.9	33
7	Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. <i>Pharmaceutical Research</i> , 2017, 34, 2749-2755.	1.7	32
8	Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 473-481.	1.4	28
9	Indole-2-Carboxamides Are Active against <i>Mycobacterium abscessus</i> in a Mouse Model of Acute Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	28
10	Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis. <i>Polymers</i> , 2017, 9, 423.	2.0	17
11	Development and validation of LC-MS/MS method for quantification of bicittegravir in human plasma and its application to an intracellular uptake study. <i>Biomedical Chromatography</i> , 2019, 33, e4379.	0.8	15
12	A Concept Evaluation Study of a New Combination Bicittegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
13	LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots. <i>Biomedical Chromatography</i> , 2018, 32, e4270.	0.8	6
14	Formulation and characterization of ternary amorphous solid dispersions of a highly potent anti-tubercular agent and curcumin. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102564.	1.4	6
15	A review of CCR5 antibodies against HIV: current and future aspects. <i>Therapeutic Delivery</i> , 2019, 10, 107-112.	1.2	5
16	Surface plasmon resonance, Orbitrap mass spectrometry and Raman advancements: exciting new techniques in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 739-743.	2.5	4
17	2501. CCR5 Targeted ARV Loaded Nanoparticle: Dual Protection for HIV Functional Cure. <i>Open Forum Infectious Diseases</i> , 2019, 6, S867-S868.	0.4	0
18	Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study. <i>Nanomaterials</i> , 2022, 12, 1942.	1.9	0